JBT-19 Human Undifferentiated Pleomorphic Sarcoma Cell Line

Soft tissue sarcomas (STS) are a rare type of tumor made up of mixed cell populations with mesenchymal features. They are classified into many histological subtypes such as undifferentiated pleomorphic sarcoma (UPS). UPS is a subtype previously known as malignant fibrous histiocytoma. UPS is associated with one of the worst prognoses of STSs and is frequently diagnosed as a high-grade tumor. Metastatic forms of this cancer have a very low 5-year survival rate of about 16%. There is also still little understanding of the UPS subtype which involves various cellular backgrounds and mutations.

Immunotherapy continues to be a strong candidate for cancer treatment in recent years. It has already shown strong results for certain cancer types that did not see effective treatment with previously traditional treatment methods. While the immunotherapy options for STS can be limited due to tumor complexity, the UPS subtype appears to show encouraging results from immunotherapy, specifically with PD-1/PD-L1 interactions. However, there is still limited availability of patient-derived UPS cell lines which has constrained the amount of preclinical research conducted so far.

The SCC649 JBT-19 undifferentiated pleomorphic sarcoma line is a strong option for continuing UPS research. The JBT-19 cell line appears to be the first introduced UPS cell line to simultaneously express PD-L1 and collagen, two important ligands of known immune checkpoint molecules, PD-1 and LAIR-1. This makes the cell line a strong candidate for immunotherapeutic research. The cell line can grow in both 2D and 3D formats in vitro as well as being able to produce solid tumors in mice when inoculated in vivo.

The JBT-19 cell line was established from a solid UPS tumor of a 65-year-old male. A combination of tumor fragmentation-dissociation techniques was used to establish the cells in an adherent monolayer.

Source
Cells were established from a solid UPS (undifferentiated pleomorphic sarcoma) primary tumor of a 65-year-old male diagnosed with the disease. Tumor was surgically removed, and the cell line was established in monolayer using a combination of tumor fragmentation dissociation techniques.

References
1. Taborska P, Lukac P, Stakheev D, Rajsiglova L, Kalkusova K, Strnadova K, Lacina L, Dvorankova B, Novotny J, Kolar M, et al. 2023. Novel PD-L1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy. Scientific Reports. 13(1).

JBT-19 undifferentiated pleomorphic sarcoma cells simultaneously express PD-L1 and collagen and are used for immunotherapeutic and cancer research.

JBT-19 cells should be stored in liquid nitrogen. The cells can be cultured for at least 10 passages without significantly affecting cell marker expression and function.

This product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact licensing@milliporesigma.com.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.